What is the history of Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD), was first formally characterized in the mid-20th century, evolving from a misunderstood movement disorder into a recognized genetic channelopathy. Historically viewed as a psychiatric condition, modern research has identified its roots in the PRRT2 gene, leading to precise diagnostic and treatment standards.

When was Paroxysmal Kinesigenic Choreathetosis first described?

While reports of transient movement disorders appeared in the early 1900s, Paroxysmal Kinesigenic Choreathetosis was distinctly defined in 1967 by Dr. George R. H. Kato, who coined the term "paroxysmal kinesigenic choreoathetosis." Before this, patients were frequently misdiagnosed with epilepsy or conversion disorders due to the sudden, involuntary nature of the movements, which are triggered by unexpected physical motion.

How has the understanding of Paroxysmal Kinesigenic Dyskinesia evolved?

For decades, clinicians struggled to classify whether Paroxysmal Kinesigenic Dyskinesia was a form of epilepsy. It was only through the advancement of neurogenetics in 2011 that researchers discovered mutations in the PRRT2 (Proline-rich transmembrane protein 2) gene. This breakthrough confirmed that the disease is a channelopathy—a disorder of ion channels in the brain—rather than a psychological or seizure-based condition.

What are the major milestones in managing this condition?

The history of treatment for Paroxysmal Kinesigenic Choreathetosis has shifted from trial-and-error to targeted management. Key milestones include:

• 1960s-70s: Initial discovery that anticonvulsants, particularly phenytoin, could suppress attacks.


• 1980s: Recognition of carbamazepine as a highly effective, low-dose maintenance therapy.


• 2011: Identification of the PRRT2 gene, allowing for definitive genetic testing.


• Modern Era: Shift toward personalized medicine, minimizing the trial of unnecessary psychiatric medications.

How has patient awareness changed?

Historical misconceptions often led to social stigma for those living with Paroxysmal Kinesigenic Dyskinesia. Today, platforms like DiseaseMaps.org empower the 7 community members currently registered to share experiences, replacing isolation with shared clinical knowledge. Increased awareness ensures that patients are now directed to neurologists specializing in movement disorders rather than psychiatric care.

Next steps

• Consult a movement disorder specialist or neurologist for a formal evaluation.


• Discuss PRRT2 genetic testing with a clinical geneticist to confirm a diagnosis.


• Join the DiseaseMaps.org community to connect with others managing Paroxysmal Kinesigenic Choreathetosis.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• NIH GARD (Genetic and Rare Diseases Information Center) - Paroxysmal Kinesigenic Dyskinesia.


• Orphanet (ORPHA:168536) - Paroxysmal kinesigenic choreoathetosis.


• OMIM (Online Mendelian Inheritance in Man) - #128200 (PKD1).


• PubMed: "The clinical and genetic spectrum of PRRT2-associated disorders."